Caffeine
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | monograph |
Pregnancy category | |
Dependence liability | Low–moderate[1] No addiction liability[1] |
Routes o admeenistration | oral, insufflation, enema, rectal, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 99% |
Protein bindin | 25–36%[2] |
Metabolism | Primarily CYP1A2;[2] Other enzymes: CYP2E1, CYP2C8, CYP2C9, CYP3A4[2] |
Biological hauf-life | Adults: 3–7 hours[2] Neonates: 65–130 hours[2] |
Excretion | urine (100%) |
Identifiers | |
| |
Synonyms | Methyltheobromine |
CAS Nummer | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
ECHA InfoCard | 100.000.329 |
Chemical and physical data | |
Formula | C8H10N4O2 |
Molar mass | 194.19 g/mol |
3D model (Jmol) | |
Density | 1.23 g/cm3 |
Meltin pynt | 235 tae 238 °C (455 tae 460 °F) (anhydrous) |
Bylin pynt | 178 °C (352 °F) (sublimes) |
| |
|
Caffeine (/kæˈfiːn, ˈkæfiːn, ˈkæfiːɪn/) is a bitter, white crystalline xanthine alkaloid an a stimulant drug.
References
[eedit | eedit soorce]- ↑ a b Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY (ed.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 375. ISBN 9780071481274.
Long-term caffeine use can lead to mild physical dependence. A withdrawal syndrome characterized by drowsiness, irritability, and headache typically lasts no longer than a day. True compulsive use of caffeine has not been documented.
CS1 maint: multiple names: authors leet (link) - ↑ a b c d e "Caffeine". DrugBank. University of Alberta. 16 September 2013. Retrieved 8 August 2014.
|section=
ignored (help)